Transgene to Discuss Myvac® Platform at Investor Access Event
News related to:Transgene · 2 min read
Strasbourg, France, October 1, 2026 /CourierPR/ -- Transgene, a biotech company developing myvac®, an individualized neoantigen therapeutic vaccines (INTV) platform, will participate in the upcoming Investor Access Event on October 6, 2026, in Paris. Organized by Investor Access, the event is designed to connect listed companies with professional investors through targeted, pre-arranged meetings with management teams. More than 190 professional investors and 90 listed companies are expected to attend.
During the event, Transgene's management team will discuss the progress of its myvac® platform, specifically focusing on TG4050, which is in clinical development for the adjuvant treatment of head and neck cancer, and TG4070, which is in Phase 1 clinical development for the adjuvant treatment of non-small cell lung cancer. The company will also present other virus-based programs from its emerging pipeline.
Transgene's myvac® platform is designed to develop individualized neoantigen therapeutic vaccines, with potential across multiple solid tumor types. The company's lead asset, TG4050, has demonstrated clinical proof of principle in the adjuvant treatment of head and neck cancer. TG4070 introduces Transgene's proprietary AI-driven neoantigen selection and scalable cell-line manufacturing capabilities. The company's other viral vector-based assets include BT-001, an oncolytic virus based on the Invir.IO® viral backbone, which is in clinical development.
Transgene's management team will also discuss the company's efforts to leverage its MVA and cell-line manufacturing expertise to develop TG-MVA™, a next-generation prophylactic vaccine candidate against mpox and smallpox. The company is also building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses through its proprietary Invir.IO® platform.
The event will take place from 5:45 pm CET, and Transgene's participation is part of a broader strategy to engage with the investment community and share updates on its pipeline and clinical progress. The company's commitment to advancing precision medicine through its innovative therapeutic vaccination approach is highlighted by the inclusion of TG4050 and TG4070 in the discussion.
Transgene's myvac® platform represents a significant step forward in the field of cancer treatment, with the potential to tailor immunotherapies to each individual patient. The company's ability to integrate AI-driven neoantigen selection and scalable cell-line manufacturing capabilities into its pipeline underscores its dedication to innovation and patient-centric approaches.
The event is organized by Investor Access, which connects listed companies with professional investors through targeted, pre-arranged meetings. More than 190 professional investors and 90 listed companies are expected to participate, making it a significant platform for Transgene to showcase its progress and engage with potential partners and investors.